Serum Soluble Interleukin-2 Receptor Does Not Differentiate Complex Regional Pain Syndrome from Other Pain Conditions in a Tertiary Referral Setting
Previously, we showed that serum soluble interleukin-2 receptor (sIL-2R) levels, a marker for T-cell activation, were higher in complex regional pain syndrome (CRPS) patients than in healthy controls, suggesting pathogenic T-cell activation in CRPS. Additionally, sIL-2R levels discriminated well bet...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2020/6259064 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563401354641408 |
|---|---|
| author | K. D. Bharwani M. Dirckx D. L. Stronks W. A. Dik F. J. P. M. Huygen |
| author_facet | K. D. Bharwani M. Dirckx D. L. Stronks W. A. Dik F. J. P. M. Huygen |
| author_sort | K. D. Bharwani |
| collection | DOAJ |
| description | Previously, we showed that serum soluble interleukin-2 receptor (sIL-2R) levels, a marker for T-cell activation, were higher in complex regional pain syndrome (CRPS) patients than in healthy controls, suggesting pathogenic T-cell activation in CRPS. Additionally, sIL-2R levels discriminated well between CRPS and healthy controls with a high sensitivity (90%) and specificity (89.5%), suggesting a possible role for sIL-2R in the diagnosis of CRPS. In order to further validate this marker in the diagnostic workup of CRPS, we conducted this prospective cohort study in which we determined sIL-2R levels in patients that were referred to our tertiary referral center with a suspicion of CRPS in a limb, and subsequently compared sIL-2R levels between the patients that were diagnosed with CRPS (CRPS group) and those who were not (no CRPS group). A group of anonymous blood bank donors were used as a healthy control group. Furthermore, we explored the relationship between sIL-2R and CRPS disease severity using the CRPS severity score. Median sIL-2R levels of both the CRPS group (2809.0 pg/ml; Q3-Q1: 3913.0-1589.0) and no CRPS group (3654.0 pg/ml; Q3-Q1: 4429.0-2095.5) were significantly higher than that of the control group (1515.0 pg/ml; Q3-Q1: 1880.0-1150.0): CRPS vs. controls, p<.001; no CRPS vs. controls, p<0.001. Serum sIL-2R levels did not differ significantly between the CRPS and no CRPS group. A statistically significant negative correlation was observed between sIL-2R levels and the CRPS severity score (rs=−0.468, p=0.024). Our results confirm our previous findings of higher sIL-2R levels in CRPS patients than in healthy controls. We further showed that serum sIL-2R cannot differentiate between CRPS and other pain conditions of a limb in a tertiary referral setting. Interestingly, a negative correlation was found between sIL-2R and CRPS disease severity; this finding warrants further research into the relationship between sIL-2R and CRPS disease severity. |
| format | Article |
| id | doaj-art-ffb0a294acfa4a5e90d23af88531f380 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-ffb0a294acfa4a5e90d23af88531f3802025-02-03T01:20:20ZengWileyMediators of Inflammation0962-93511466-18612020-01-01202010.1155/2020/62590646259064Serum Soluble Interleukin-2 Receptor Does Not Differentiate Complex Regional Pain Syndrome from Other Pain Conditions in a Tertiary Referral SettingK. D. Bharwani0M. Dirckx1D. L. Stronks2W. A. Dik3F. J. P. M. Huygen4Center for Pain Medicine, Department of Anesthesiology, Erasmus MC University Medical Center Rotterdam, NetherlandsCenter for Pain Medicine, Department of Anesthesiology, Erasmus MC University Medical Center Rotterdam, NetherlandsCenter for Pain Medicine, Department of Anesthesiology, Erasmus MC University Medical Center Rotterdam, NetherlandsLaboratory Medical Immunology, Department of Immunology, Erasmus MC University Medical Center Rotterdam, NetherlandsCenter for Pain Medicine, Department of Anesthesiology, Erasmus MC University Medical Center Rotterdam, NetherlandsPreviously, we showed that serum soluble interleukin-2 receptor (sIL-2R) levels, a marker for T-cell activation, were higher in complex regional pain syndrome (CRPS) patients than in healthy controls, suggesting pathogenic T-cell activation in CRPS. Additionally, sIL-2R levels discriminated well between CRPS and healthy controls with a high sensitivity (90%) and specificity (89.5%), suggesting a possible role for sIL-2R in the diagnosis of CRPS. In order to further validate this marker in the diagnostic workup of CRPS, we conducted this prospective cohort study in which we determined sIL-2R levels in patients that were referred to our tertiary referral center with a suspicion of CRPS in a limb, and subsequently compared sIL-2R levels between the patients that were diagnosed with CRPS (CRPS group) and those who were not (no CRPS group). A group of anonymous blood bank donors were used as a healthy control group. Furthermore, we explored the relationship between sIL-2R and CRPS disease severity using the CRPS severity score. Median sIL-2R levels of both the CRPS group (2809.0 pg/ml; Q3-Q1: 3913.0-1589.0) and no CRPS group (3654.0 pg/ml; Q3-Q1: 4429.0-2095.5) were significantly higher than that of the control group (1515.0 pg/ml; Q3-Q1: 1880.0-1150.0): CRPS vs. controls, p<.001; no CRPS vs. controls, p<0.001. Serum sIL-2R levels did not differ significantly between the CRPS and no CRPS group. A statistically significant negative correlation was observed between sIL-2R levels and the CRPS severity score (rs=−0.468, p=0.024). Our results confirm our previous findings of higher sIL-2R levels in CRPS patients than in healthy controls. We further showed that serum sIL-2R cannot differentiate between CRPS and other pain conditions of a limb in a tertiary referral setting. Interestingly, a negative correlation was found between sIL-2R and CRPS disease severity; this finding warrants further research into the relationship between sIL-2R and CRPS disease severity.http://dx.doi.org/10.1155/2020/6259064 |
| spellingShingle | K. D. Bharwani M. Dirckx D. L. Stronks W. A. Dik F. J. P. M. Huygen Serum Soluble Interleukin-2 Receptor Does Not Differentiate Complex Regional Pain Syndrome from Other Pain Conditions in a Tertiary Referral Setting Mediators of Inflammation |
| title | Serum Soluble Interleukin-2 Receptor Does Not Differentiate Complex Regional Pain Syndrome from Other Pain Conditions in a Tertiary Referral Setting |
| title_full | Serum Soluble Interleukin-2 Receptor Does Not Differentiate Complex Regional Pain Syndrome from Other Pain Conditions in a Tertiary Referral Setting |
| title_fullStr | Serum Soluble Interleukin-2 Receptor Does Not Differentiate Complex Regional Pain Syndrome from Other Pain Conditions in a Tertiary Referral Setting |
| title_full_unstemmed | Serum Soluble Interleukin-2 Receptor Does Not Differentiate Complex Regional Pain Syndrome from Other Pain Conditions in a Tertiary Referral Setting |
| title_short | Serum Soluble Interleukin-2 Receptor Does Not Differentiate Complex Regional Pain Syndrome from Other Pain Conditions in a Tertiary Referral Setting |
| title_sort | serum soluble interleukin 2 receptor does not differentiate complex regional pain syndrome from other pain conditions in a tertiary referral setting |
| url | http://dx.doi.org/10.1155/2020/6259064 |
| work_keys_str_mv | AT kdbharwani serumsolubleinterleukin2receptordoesnotdifferentiatecomplexregionalpainsyndromefromotherpainconditionsinatertiaryreferralsetting AT mdirckx serumsolubleinterleukin2receptordoesnotdifferentiatecomplexregionalpainsyndromefromotherpainconditionsinatertiaryreferralsetting AT dlstronks serumsolubleinterleukin2receptordoesnotdifferentiatecomplexregionalpainsyndromefromotherpainconditionsinatertiaryreferralsetting AT wadik serumsolubleinterleukin2receptordoesnotdifferentiatecomplexregionalpainsyndromefromotherpainconditionsinatertiaryreferralsetting AT fjpmhuygen serumsolubleinterleukin2receptordoesnotdifferentiatecomplexregionalpainsyndromefromotherpainconditionsinatertiaryreferralsetting |